Genfit (GNFT) Corporate Presentation summary

Corporate and financial highlights

• Dual-listed French biopharma focused on rare and severe liver diseases, with expertise in advancing early-stage assets to commercial readiness.

• Cash position of €96M as of September 30, 2024, with a projected runway through Q4 2025, factoring in expected milestone revenues.

• Received €48.7M milestone payment and €0.9M royalty revenue from Ipsen in June 2024 for Iqirvo® (elafibranor) sales.

• Iqirvo® (elafibranor) approved by FDA, EMA, and UK authorities for PBC in 2024, with commercialization by Ipsen.

Strategic focus and pipeline

• Shifted focus to rare, life-threatening liver diseases, especially acute-on-chronic liver failure (ACLF), with six programs in ACLF and two in other severe liver conditions.

• Pipeline includes VS-01 (Phase 2), NTZ (proof of concept), SRT-015 (first-in-human), CLM-022 (preclinical), and VS-02-HE (preclinical) for ACLF.

• GNS561 in Phase 2 for other life-threatening liver diseases; diagnostic programs in development.

• Multiple clinical data readouts and study initiations targeted for 2025 across pipeline assets.

ACLF disease landscape and unmet need

• ACLF is a severe, resource-intensive condition with high short-term mortality, affecting mainly males around 55 years old.

• No direct therapeutic exists; current management is supportive care and liver transplantation, which is limited by timing and organ availability.

• Systemic inflammation, altered microbiome, and portal hypertension are key drivers of ACLF pathogenesis.

• Economic burden is significant, with average US hospitalization costs of $52,000 and annual burden of $6.4B.